A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Effective April 7, 2022, registration to Cohort C: Squamous Cell Carcinoma of the Bladder is temporarily suspended.
Effective August 12, 2021, registration to Cohort F: Sarcomatoid Renal Cell Carcinoma is temporarily suspended.
Effective June 23, 2021, registration to Cohort I: Renal Medullary Carcinoma Cohort is temporarily suspended.
Effective June 16, 2021, registration to Cohort B: Adenocarcinoma of the Bladder is temporarily suspended.
Effective April 21, 2021, registration to Cohort A: Small Cell Carcinoma of the Bladder is temporarily suspended.
Effective March 12, 2020, registration to Cohort E: Penile Cancer is temporarily suspended.
Effective July 20, 2020, registration to Cohort G: Miscellaneous GU Tract Histologic Variants cohort (Cohort G) is temporarily suspended.
